The stock of Antares Pharma Inc (NASDAQ:ATRS) is a huge mover today! About 269,698 shares traded hands. Antares Pharma Inc (NASDAQ:ATRS) has risen 92.16% since April 22, 2016 and is uptrending. It has outperformed by 86.75% the S&P500.
The move comes after 9 months positive chart setup for the $322.89 million company. It was reported on Nov, 25 by Barchart.com. We have $2.10 PT which if reached, will make NASDAQ:ATRS worth $16.14M more.
Analysts await Antares Pharma Inc (NASDAQ:ATRS) to report earnings on March, 14. They expect $-0.04 earnings per share, 0.00% or $0.00 from last year’s $-0.04 per share. After $-0.04 actual earnings per share reported by Antares Pharma Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
According to Zacks Investment Research, “Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy.”
Insitutional Activity: The institutional sentiment increased to 0.82 in 2016 Q2. Its up 0.19, from 0.63 in 2016Q1. The ratio improved, as 28 funds sold all Antares Pharma Inc shares owned while 21 reduced positions. 16 funds bought stakes while 15 increased positions. They now own 55.56 million shares or 16.31% less from 66.39 million shares in 2016Q1.
Blackrock Fund last reported 26,842 shares in the company. Blackrock Advsr Limited last reported 0% of its portfolio in the stock. First Eagle Ltd Com has invested 0% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS). Commonwealth Equity Service reported 43,400 shares or 0% of all its holdings. Lmr Prns Limited Liability Partnership accumulated 0.05% or 282,738 shares. Deutsche Commercial Bank Ag, a Germany-based fund reported 230,825 shares. Citigroup accumulated 8,362 shares or 0% of the stock. Royal State Bank Of Canada has 0% invested in the company for 10,350 shares. The Wisconsin-based Sii Invests Wi has invested 0% in Antares Pharma Inc (NASDAQ:ATRS). Oxford Asset Mgmt accumulated 47,032 shares or 0% of the stock. Morgan Stanley accumulated 0% or 85,764 shares. Thompson Davis & Incorporated, a Virginia-based fund reported 19,421 shares. Northern Corp holds 252,188 shares or 0% of its portfolio. Moreover, Credit Suisse Ag has 0% invested in Antares Pharma Inc (NASDAQ:ATRS) for 537,318 shares. Renaissance Tech Ltd Liability Com holds 0.01% of its portfolio in Antares Pharma Inc (NASDAQ:ATRS) for 2.72 million shares.
More news for Antares Pharma Inc (NASDAQ:ATRS) were recently published by: Globenewswire.com, which released: “Antares Pharma to Present at the 28th Annual Piper Jaffray Healthcare Conference” on November 23, 2016. Seekingalpha.com‘s article titled: “Antares Pharmaceuticals: The Stock To Buy On EpiPen Issues” and published on August 28, 2016 is yet another important article.
ATRS Company Profile
Antares Pharma, Inc. (Antares), incorporated on April 29, 2005, is a specialty pharmaceutical firm that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Firm develops and makes pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Firm makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Firm operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.